Ability of ELISA and a toxin neutralization assay to detect changes in immunogenicity of a recombinant Bacillus anthracis protective antigen vaccine upon storage

Biologicals

Volumn 41, Issue 2, 2013, Pages 111-114

  Domínguez Castillo, Rocío I ^a   Verma, Anita ^a   Amador Molina, Juan C ^a   Sirota, Lev ^a   Arciniega, Juan L ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

ELISA; Potency test; RPA based anthrax vaccine; TNA

Indexed keywords

ALUMINUM; ANTHRAX VACCINE; RECOMBINANT ANTIGEN; RECOMBINANT PROTECTIVE ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BACILLUS ANTHRACIS; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG POTENCY; DRUG STORAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNIZATION; IMMUNOASSAY; IMMUNOGENICITY; INTERMETHOD COMPARISON; MOUSE; NONHUMAN; PRIORITY JOURNAL; ROOM TEMPERATURE; SINGLE DRUG DOSE; STORAGE TEMPERATURE; TOXIN NEUTRALIZATION ASSAY;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; CELL LINE; CELL SURVIVAL; DRUG STORAGE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNIZATION; MICE; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; TEMPERATURE; TIME FACTORS;

BACILLUS ANTHRACIS;

EID: 84875249020     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2012.10.002     Document Type: Article

References (20)

1. Borio L., Frank D., Mani V., Chiriboga C., Pollanen M., Ripple M., et al. Death due to bioterrorism-related inhalational anthrax: report of 2 patients. JAMA: The Journal of the American Medical Association 2001, 286:2554-2559.
2. Friedlander A.M. Anthrax: clinical features, pathogenesis, and potential biological warfare threat. Current Clinical Topics in Infectious Diseases 2000, 20:335-349.
3. Baillie L.W. Is new always better than old?: the development of human vaccines for anthrax. Human Vaccines 2009, 5:806-816.
4. Young J.A., Collier R.J. Anthrax toxin: receptor binding, internalization, pore formation, and translocation. Annual Review of Biochemistry 2007, 76:243-265.
5. Kobiler D. Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization. Infection and Immunity 2002, 70:544-560.
6. Friedlander A.M., Little S.F. Advances in the development of next-generation anthrax vaccines. Vaccine 2009, 27(Suppl. 4):D28-D32.
7. Convention USP.United States Pharmacopeia (USP 35 NF 30) Anthrax vaccine adsorbed 2012, United States Pharmacopeia, Rockville, MD.
8. Little S.F., Webster W.M., Ivins B.E., Fellows P.F., Norris S.L., Andrews G.P. Development of an in vitro-based potency assay for anthrax vaccine. Vaccine 2004, 22:2843-2852.
9. Pombo M., Berthold I., Gingrich E., Jaramillo M., Leef M., Sirota L., et al. Validation of an anti-PA-ELISA for the potency testing of anthrax vaccine in mice. Biologicals: Journal of the International Association of Biological Standardization 2004, 32:157-163.
10. Hering D., Thompson W., Hewetson J., Little S., Norris S., Pace-Templeton J. Validation of the anthrax lethal toxin neutralization assay. Biologicals: Journal of the International Association of Biological Standardization 2004, 32:17-27.
11. Parreiras P.M., Sirota L.A., Wagner L.D., Menzies S.L., Arciniega J.L. Comparability of ELISA and toxin neutralization to measure immunogenicity of protective antigen in mice, as part of a potency test for anthrax vaccines. Vaccine 2009, 27:4537-4542.
12. Castelan-Vega J., Corvette L., Sirota L., Arciniega J. Reduction of immunogenicity of anthrax vaccines subjected to thermal stress, as measured by a toxin neutralization assay. Clinical and Vaccine Immunology: CVI 2011, 18:349-351.
13. Jimenez-Alberto A., Parreiras P., Castelan-Vega J., Sirota L., Arciniega J. Feasibility of the use of ELISA in an immunogenicity-based potency test of anthrax vaccines. Biologicals: Journal of the International Association of Biological Standardization 2011, 39:236-241.
14. Berthold I., Pombo M.L., Wagner L., Arciniega J.L. Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants. Vaccine 2005, 23:1993-1999.
15. Quinn C.P., Dull P.M., Semenova V., Li H., Crotty S., Taylor T.H., et al. Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. The Journal of Infectious Diseases 2004, 190:1228-1236.
16. Reizenstein E., Hallander H.O., Blackwelder W.C., Kuhn I., Ljungman M., Mollby R. Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model. Journal of Immunological Methods 1995, 183:279-290.
17. Zar J.H. Biostatistical analysis 1999, Prentice Hall, New Jersey, p. 228.
18. Reuveny S., White M.D., Adar Y.Y., Kafri Y., Altboum Z., Gozes Y., et al. Search for correlates of protective immunity conferred by anthrax vaccine. Infection and Immunity 2001, 69:2888-2893.
19. Chalton D.A., Kelly I.F., McGregor A., Ridley H., Watkinson A., Miller J., et al. Unfolding transitions of Bacillus anthracis protective antigen. Archives of Biochemistry and Biophysics 2007, 465:1-10.
20. Singh S., Singh A., Aziz M.A., Waheed S.M., Bhat R., Bhatnagar R. Thermal inactivation of protective antigen of Bacillus anthracis and its prevention by polyol osmolytes. Biochemical and Biophysical Research Communications 2004, 322:1029-1037.